Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Videos [5127]

AlloHCT conditioning intensity in AML in complete remission with residual...

Dr Christopher Hourigan - National Heart, Lung, and Blood Institute, Bethesda...

AlloHCT conditioning intensity in AML in complete remission with residual disease ( Dr Christopher Hourigan - National Heart, Lung, and Blood Institute, Bethesda, USA )

ASCEND: Acalabrutinib versus rituximab with idelalisib or bendamustine in...

Prof Paolo Ghia - Vita-Salute San Raffaele University, Milan, Italy

$ASCEND: Acalabrutinib versus rituximab with idelalisib or bendamustine in relapsed or refractory CLL ( Prof Paolo Ghia - Vita-Salute San Raffaele University, Milan, Italy )$

Inhibition of NADK strongly inhibits T-ALL cells from growing

Dr Etienne De Braekeleer - Wellcome Sanger Institute, Cambridge, UK

Inhibition of NADK strongly inhibits T-ALL cells from growing ( Dr Etienne De Braekeleer - Wellcome Sanger Institute, Cambridge, UK )

Novel immunotherapy 5F9 plus rituximab well tolerated with rapid and durable...

Dr Mark Roschewski - National Cancer Institute, Bethesda, USA

Novel immunotherapy 5F9 plus rituximab well tolerated with rapid and durable responses in R/R DLBCL and indolent lymphoma ( Dr Mark Roschewski - National Cancer Institute, Bethesda, USA )

Venetoclax with bortezomib and dexamethasone shows good response but higher...

Dr Shaji Kumar - Mayo Clinic, Rochester, USA

Venetoclax with bortezomib and dexamethasone shows good response but higher risk of treatment related death in RRMM ( Dr Shaji Kumar - Mayo Clinic, Rochester, USA )

Acalabrutinib monotherapy shows significant benefit in relapsed or refractory...

Dr Paolo Ghia - Vita-Salute San Raffaele University, Milan, Italy

$Acalabrutinib monotherapy shows significant benefit in relapsed or refractory chronic lymphocytic leukaemia ( Dr Paolo Ghia - Vita-Salute San Raffaele University, Milan, Italy )$

Imetelstat provides durable transfusion independence in heavily transfused non...

Dr Pierre Fenaux - Hôpital St Louis and Paris University, Paris, France

Imetelstat provides durable transfusion independence in heavily transfused non-del(5q) LR-MDS R/R to ESAS ( Dr Pierre Fenaux - Hôpital St Louis and Paris University, Paris, France )

D-VTd in induction prior to and consolidation after ASCT improves PFS and depth...

Prof Philippe Moreau - Chu Nantes, Nantes, France

D-VTd in induction prior to and consolidation after ASCT improves PFS and depth of response with acceptable safety ( Prof Philippe Moreau - Chu Nantes, Nantes, France )

Venetoclax plus obinutuzumab improves PFS and MRD-negativity in patients with...

Dr Kirsten Fischer - Uniklinik Köln, Cologne, Germany

Venetoclax plus obinutuzumab improves PFS and MRD-negativity in patients with previously untreated CLL and comorbidities ( Dr Kirsten Fischer - Uniklinik Köln, Cologne, Germany )

Intervention for AML patients with MRD can result in improved survival

Dr Christopher Hourigan - Laboratory of Myeloid Malignancies, National Heart...

Intervention for AML patients with MRD can result in improved survival ( Dr Christopher Hourigan - Laboratory of Myeloid Malignancies, National Heart, Lung, and Blood Institute, NIH, Bethesda, USA )

CALGB 90601: Comparing gemcitabine and cisplatin with bevacizumab to placebo...

Dr Jonathan Rosenberg - Memorial Sloan-Kettering Cancer Institute, New York, USA

CALGB 90601: Comparing gemcitabine and cisplatin with bevacizumab to placebo for metastatic urothelial carcinoma ( Dr Jonathan Rosenberg - Memorial Sloan-Kettering Cancer Institute, New York, USA )

Maintenance pembrolizumab vs placebo for metastatic urothelial cancer

Prof Matthew Galsky - The Mount Sinai Hospital, New York, USA

Maintenance pembrolizumab vs placebo for metastatic urothelial cancer ( Prof Matthew Galsky - The Mount Sinai Hospital, New York, USA )

More from ecancer